MyFinsight
Home
Blog
About
Contact
Download
Download image
Biopharma
Segment-Operating Segments
$14,161M
(5.36%↑ Y/Y)
Corporate Non Segment
$289M
(5.86%↑ Y/Y)
Total revenues
$14,451M
(5.37%↑ Y/Y)
Income from continuing
operations before...
$3,170M
(13.82%↑ Y/Y)
Cost of sales
$3,548M
(24.71%↑ Y/Y)
Selling, informational
and administrative...
$2,961M
(-2.31%↓ Y/Y)
Research and development
expenses
$2,490M
(13.03%↑ Y/Y)
Amortization of intangible
assets
$1,183M
(-2.31%↓ Y/Y)
Other
(income)/deductionsnet
-$861M
(9.65%↑ Y/Y)
Acquired in-process
research and development...
$137M
(1422.22%↑ Y/Y)
Restructuring charges and
certain...
$100M
(-85.25%↓ Y/Y)
Income from continuing
operations
$2,709M
(-8.88%↓ Y/Y)
Provision/(benefit) for taxes on
income
$461M
(343.92%↑ Y/Y)
Net income before
allocation to...
$2,696M
(-9.32%↓ Y/Y)
Discontinued operationsnet
of tax
-$13M
Net income
attributable to pfizer inc....
$2,687M
(-9.44%↓ Y/Y)
Less net income
attributable to...
$8M
(33.33%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Pfizer_(2021)-svg
PFIZER INC (PFE)
Pfizer_(2021)-svg
PFIZER INC (PFE)